Kesimpta mechanism?

How does Kesimpta (ofatumumab) work?

Kesimpta’s active ingredient, ofatumumab, is a monoclonal antibody that targets CD20 on B cells. By binding to CD20, it depletes B cells and reduces the activity of the immune system in ways that help treat multiple sclerosis.[1]

What does targeting CD20 do to the immune system?

CD20 is present on the surface of B lymphocytes. When ofatumumab attaches to CD20, it drives B-cell depletion, which lowers the number of B cells available to contribute to the inflammatory immune processes associated with multiple sclerosis.[1]

Is Kesimpta a “B-cell depleter,” and how is that different from other MS drugs?

Yes. Kesimpta is classified as a B-cell depleting therapy because its key action is reducing circulating B cells through CD20 targeting.[1]

What does this mean for patients in practical terms?

Because Kesimpta’s effect centers on B-cell reduction, its treatment approach aims to prevent immune-mediated damage by cutting down B-cell activity rather than only blocking inflammation pathways downstream.[1]

Source

[1] https://www.drugs.com/monograph/kesimpta-injection.html